Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2024-12-31 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
CONTINUING CONNECTED TRANSACTIONS STRATEGIC COOPERATION AGREEMENTS 2025
Regulatory Filings Classification · 92% confidence The document is a Hong Kong Stock Exchange announcement regarding the company’s continuing connected transactions under Chapter 14A of the Listing Rules, setting out strategic cooperation agreements and annual caps for transactions with related parties. It is not an earnings release, annual report, management discussion, or call transcript, but a regulatory announcement of agreements. This does not fit any of the more specific categories, so it falls under the fallback Regulatory Filings category.
2024-12-31 English
CONTINUING CONNECTED TRANSACTIONS CR LEASING STRATEGIC COOPERATION AGREEMENT 2025
Regulatory Filings Classification · 90% confidence The document is a Hong Kong Stock Exchange announcement concerning continuing connected transactions (CR Leasing Strategic Cooperation Agreement 2025) under Chapter 14A of the Listing Rules. It is not a full financial report (10-K, IR), earnings release, manager discussion, or other specific category. It constitutes a regulatory announcement of a material transaction and therefore falls under the fallback category of Regulatory Filings (RNS).
2024-12-31 English
CONTINUING CONNECTED TRANSACTIONS THE PROCUREMENT FRAMEWORK AGREEMENT 2025 AND THE PRODUCTS AND COMMODITIES SALES FRAMEWORK AGREEMENT 2025
Regulatory Filings Classification · 93% confidence The document is a Hong Kong Stock Exchange announcement detailing two continuing connected transactions (framework agreements for procurement and products/commodities sales) with a controlling shareholder under Chapter 14A of the Listing Rules. It is not an annual or interim financial report, earnings release, board change, dividend notice, nor a proxy solicitation. It is a regulatory announcement of related-party transactions that does not fit into any more specific category, so it falls under Regulatory Filings (RNS).
2024-12-31 English
CONTINUING CONNECTED TRANSACTIONS THE IT SERVICES PROCUREMENT FRAMEWORK AGREEMENT 2025
Regulatory Filings Classification · 80% confidence The document is an announcement published on the Hong Kong Stock Exchange regarding a continuing connected transaction (IT Services Procurement Framework Agreement 2025) under Chapter 14A of the HK Listing Rules. It is not an investor presentation, financial report, earnings release, share issuance, or any of the more specific categories. Therefore, it should be classified under the general "Regulatory Filings" category (RNS) as a miscellaneous regulatory announcement.
2024-12-30 English
CONTINUING CONNECTED TRANSACTIONS THE AMENDED BUSINESS TRAVEL SERVICES FRAMEWORK AGREEMENT 2025
Regulatory Filings Classification · 90% confidence The document is an exchange announcement by China Resources Pharmaceutical Group Limited regarding the terms, caps, and details of its "Continuing Connected Transactions" under Chapter 14A of the HKEX Listing Rules. It is not an earnings release, not a corporate governance report, nor a proxy statement or dividend notice, and there is no dedicated category for connected-transaction announcements. Therefore, it falls under the general “Regulatory Filings” fallback category (RNS).
2024-12-30 English
TERMS OF REFERENCE FOR EXECUTIVE COMMITTEE (REVISED)
Governance Information Classification · 90% confidence The document is titled “Terms of Reference for Executive Committee” and outlines the structure, membership, duties, authority, and reporting procedures of a board committee. It defines governance practices and internal rules rather than reporting financial results or announcing changes, fitting squarely into Governance Information (CGR).
2024-12-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.